“CMC-544 (inotuzumab ozogamicin): A CD22-Targeted Immunoconjugate of Calicheamicin”. Hematology Meeting Reports 2, no. 5 (June 23, 2009). Accessed August 7, 2025. https://journals.pagepress.org/hmr/article/view/735.